fda warning letters compounded semaglutide tirzepatide 2025 and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What's Next? Congress Introduces SAFE Drugs Act

Studies have explored its effects on: Enhancing glucose-dependent insulin secretion, Reducing glucagon release, Delaying gastric emptying, Modulating appetite and satiety pathways

since publication of the SELECT trial results, semaglutide is now approved for use by the US Food and Drug Administration (FDA) to reduce the risk of MACE in adults with established CVD and obesity or overweight [22], in addition to regulatory approval by the European Medicines Agency (EMA) and other major markets

Leaky gut is a non-clinical umbrella term often used to describe situations where intestinal permeability increases beyond its healthy regulatory range

Mognetti B, Marino S, Barberis A, Martin AS, Bala Y, Di Carlo F, et al

For many, the impact on quality of life makes the combination unsustainable